Can tenascin - X be a marker of bone turnover in patients with Ehlers-Danlos syndrome?

- Łapan Aleksandra Żuk; Babula Emilia; Poprawa Iga; Podstawka Jakub; Julia Latocha; Zuzanna Szymańska; Domański Jan; Zagozda Małgorzata; Wilk Juliusz; Korcz Tomasz; Cicha-Brzezińska Małgorzata; Bernadetta Kaluza; Edward Franek

doi:10.1530/endoabs.99.EP750

EP750

Prev Next

Section Contents Cite

Endocrine Abstracts (2024) 99 EP750 | DOI: 10.1530/endoabs.99.EP750

ECE2024 Eposter Presentations Calcium and Bone (102 abstracts)

Can tenascin - X be a marker of bone turnover in patients with Ehlers-Danlos syndrome?

Aleksandra Żuk - Łapan , Babula Emilia , Poprawa Iga , Podstawka Jakub , Julia Latocha , Zuzanna Szymańska , Domański Jan , Zagozda Małgorzata , Wilk Juliusz , Korcz Tomasz , Cicha-Brzezińska Małgorzata , Bernadetta Kaluza & Edward Franek

Err

Author affiliations

National Medical Institute of the Ministry of the Interior and Administration in Warsaw, Warszawa, Poland

Background: The alterations in collagen synthesis and connective tissue structure that occur in Ehlers–Danlos syndrome translate to an increased risk of bone mass loss and development of osteopenia and osteoporosis, which may be evaluated with bone turnover biomarkers. Some subtypes of Ehlers–Danlos syndrome are associated with structural alterations in the extracellular matrix glycoprotein tenascin-X. The purpose of this study was to assess the relationship between tenascin-X and both bone turnover markers and bone mineral density (BMD) in patients with Ehlers–Danlos syndrome.

Material and methods: This study involved a prospective evaluation of 30 female patients, aged 20–53 years, with hypermobile or classical Ehlers–Danlos syndrome. All patients underwent tests of their tenascin-X levels, calcium and phosphorus metabolism parameters, and BMD scans of the femoral neck and lumbar spine.

Results: The study showed no significant correlation between tenascin-X levels on one hand and femoral neck BMD (r_s 0.13, P=0.49), lumbar spine BMD (r_s 0.17, P=0.36), alkaline phosphatase levels (r_s 0.18, P=0.33), beta-crossLaps levels (r_s 0.11, P=0.56), or osteocalcin levels (r_s -0.08, P=0.66). Univariate logistic regression showed no statistically significant effect of tenascin-X levels on the development of osteoporosis (OR 0.48, 95% CI 0–1.32, P=0.99).